Image

Intravascular Ultrasound-derived Assessment of Hemodynamically Negative Lesions in NSTEACS Patients

Intravascular Ultrasound-derived Assessment of Hemodynamically Negative Lesions in NSTEACS Patients

Recruiting
18-75 years
All
Phase N/A

Powered by AI

Overview

This is an observational and prospective cohort study to examine whether the addition of IVUS plaque morphological evaluation to FFR haemodynamic assessment of non-culprit lesions in NSTEACS patients will better predict MACEs.

Description

IMPACT-NSTEACS is a prospective, single-centre and dynamic observational study. The study population consists of NSTEACS patients who undergo FFR in lesions with intermediate to severe angiographic stenosis. Then, FFR-guided PCI is performed, followed by morphological assessment based on IVUS in all FFR-negative lesions (FNLs). After discharge all patients receive optimal medication treatment and are followed up clinically. On the basis of follow-up angiography, MACEs are further adjudicated as occurring at FNLs or not.

Eligibility

Clinical Inclusion Criteria:

  1. Moderate to high risk NSTEACS requiring invasive strategy based on current guidelines and local clinical practice.
  2. Patient agrees and is able to follow all protocol procedures.

Clinical Exclusion Criteria:

  1. STEMI or SCAD.
  2. Hemodynamic instability (e.g. cardiogenic shock, refractory ventricular arrhythmias, acute and severe conduction system disease and left ventricular ejection fraction ≤30%).
  3. Contraindication for FFR, PCI, IVUS and OMT (e.g. severe allergy to antiplatelet drug or contrast, significant bleed within the past 6 months, bleeding diathesis and serum creatinine ≥2.5 mg/dl).
  4. PCI within 6 months or any prior CABG.
  5. Anticipated life expectancy <3 year.
  6. Pregnancy
  7. Unwilling or unable to provide informed consent

Imaging Inclusion Criteria

  1. Patients must have at least > 1 de novo lesion in a native coronary segment with a visually estimated diameter stenosis of between 40 and 90 %.
  2. Successful FFR-guided PCI performed in all major epicardial coronary arteries (including their branches): PCI for all lesions a) with 40%-90% diameter stenosis and FFR<0.8 and b) with ≥90% diameter stenosis.
  3. The FFR-negative lesions must be available for assessment of IVUS.

Imaging Exclusion Criteria:

  1. Target lesion reference diameter <2.0 mm.
  2. Anatomic conditions precluding FFR and IVUS (e.g. marked calcification or tortuosity, chronic total occlusion or thrombus).
  3. After successful FFR-guided PCI, no FNL is left.
  4. Any remaining lesion with diameter stenosis ≥90% or FFR<0.8 after PCI.
  5. Left main coronary artery lesion.
  6. CABG planned by the investigators according to extent and severity of coronary artery disease.

Study details
    Non-ST-segment Acute Coronary Syndrome

NCT03641898

Tianjin Chest Hospital

27 January 2024

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.